inclusion criteria: 1. individuals (female, male, diverse) ≥ 18 years with sars-cov-2 infection, confirmed by pcr before study enrollment 2. sars-cov-2 positive pcr ≤ 3 days old (date of np swab) 3. presence of ≥ 1 sars-cov-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration \<= 3 days. 4. ability to provide written informed consent 5. presence of at least one of the following criteria: * patients \> 75 years * patients \> 65 years with at least one other risk factor (bmi \>35 kg/m2, coronary artery disease, chronic kidney disease (ckd) with glomerular filtration rate (gfr) \<60 ml/min but \>= 30 ml/min, diabetes mellitus, active tumor disease) * patients with a bmi \>35 kg/m2 with at least one other risk factor (cad, ckd with gfr \<60 ml/min but \>= 30 ml/min, diabetes mellitus, active tumor disease) * patients with a bmi \>40 kg/m2 * patients with chronic obstructive pulmonary disease (copd) and/or pulmonary fibrosis

inclusion criteria: 1. individuals (female, male, diverse) ≥ 18 years with sars-cov-2 infection, confirmed by pcr before study enrollment 2. sars-cov-2 positive pcr ≤ 3 days old (date of np swab) 3. presence of ≥ 1 sars-cov-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration \<= 3 days. 4. ability to provide written informed consent 5. presence of at least one of the following criteria: * patients \> 75 years * patients \> 65 years with at least one other risk factor (bmi \>35 kg/m2, coronary artery disease, chronic kidney disease (ckd) with glomerular filtration rate (gfr) \<60 ml/min but \>= 30 ml/min, diabetes mellitus, active tumor disease) * patients with a bmi \>35 kg/m2 with at least one other risk factor (cad, ckd with gfr \<60 ml/min but \>= 30 ml/min, diabetes mellitus, active tumor disease) * patients with a bmi \>40 kg/m2 * patients with chronic obstructive pulmonary disease (copd) and/or pulmonary fibrosis

inclusion criteria: individuals (female, male, diverse) ≥ 18 years with sars-cov-2 infection, confirmed by pcr before study enrollment sars-cov-2 positive pcr ≤ 3 days old (date of np swab) presence of ≥ 1 sars-cov-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration <= 3 days. ability to provide written informed consent presence of at least one of the following criteria: patients > 75 years patients > 65 years with at least one other risk factor (bmi >35 kg/m2, coronary artery disease, chronic kidney disease (ckd) with glomerular filtration rate (gfr) <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) patients with a bmi >35 kg/m2 with at least one other risk factor (cad, ckd with gfr <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) patients with a bmi >40 kg/m2 patients with chronic obstructive pulmonary disease (copd) and/or pulmonary fibrosis

inclusion criteria: individuals (female, male, diverse) ≥ 18 years with sars-cov-2 infection, confirmed by pcr before study enrollment sars-cov-2 positive pcr ≤ 3 days old (date of np swab) presence of ≥ 1 sars-cov-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration <= 3 days. ability to provide written informed consent presence of at least one of the following criteria: patients > 75 years patients > 65 years with at least one other risk factor (bmi >35 kg/m2, coronary artery disease, chronic kidney disease (ckd) with glomerular filtration rate (gfr) <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) patients with a bmi >35 kg/m2 with at least one other risk factor (cad, ckd with gfr <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) patients with a bmi >40 kg/m2 patients with chronic obstructive pulmonary disease (copd) and/or pulmonary fibrosis

inclusion criteria: 1. individuals (female, male, diverse) ≥ 18 years with sars-cov-2 infection, confirmed by pcr before study enrollment 2. sars-cov-2 positive pcr ≤ 3 days old (date of np swab) 3. presence of ≥ 1 sars-cov-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration <= 3 days. 4. ability to provide written informed consent 5. presence of at least one of the following criteria: - patients > 75 years - patients > 65 years with at least one other risk factor (bmi >35 kg/m2, coronary artery disease, chronic kidney disease (ckd) with glomerular filtration rate (gfr) <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) - patients with a bmi >35 kg/m2 with at least one other risk factor (cad, ckd with gfr <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) - patients with a bmi >40 kg/m2 - patients with chronic obstructive pulmonary disease (copd) and/or pulmonary fibrosis

inclusion criteria: 1. individuals (female, male, diverse) ≥ 18 years with sars-cov-2 infection, confirmed by pcr before study enrollment 2. sars-cov-2 positive pcr ≤ 3 days old (date of np swab) 3. presence of ≥ 1 sars-cov-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration <= 3 days. 4. ability to provide written informed consent 5. presence of at least one of the following criteria: - patients > 75 years - patients > 65 years with at least one other risk factor (bmi >35 kg/m2, coronary artery disease, chronic kidney disease (ckd) with glomerular filtration rate (gfr) <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) - patients with a bmi >35 kg/m2 with at least one other risk factor (cad, ckd with gfr <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease) - patients with a bmi >40 kg/m2 - patients with chronic obstructive pulmonary disease (copd) and/or pulmonary fibrosis